Tech Company Financing Transactions

Aiolos Bio Funding Round

On 10/25/2023, Aiolos Bio raised $245 million in Series A funding from Atlas Venture, Bain Capital Life Sciences and Forbion Capital Partners.

Transaction Overview

Company Name
Announced On
10/25/2023
Transaction Type
Venture Equity
Amount
$245,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to accelerate development of its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Clarendon St
Boston, MA 02116
USA
Phone
Undisclosed
Email Address
Overview
At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immune conditions. We're on a mission to reimagine therapies that bring hope and relief to patients and caregivers alike.Aiolos Bio is an accomplished team of seasoned drug developers with decades of industry experience and operational leadership. With over 30 FDA approvals, we've successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more.
Profile
Aiolos Bio LinkedIn Company Profile
Social Media
Aiolos Bio Company Twitter Account
Company News
Aiolos Bio News
Facebook
Aiolos Bio on Facebook
YouTube
Aiolos Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Khurem Farooq
  Khurem Farooq LinkedIn Profile  Khurem Farooq Twitter Account  Khurem Farooq News  Khurem Farooq on Facebook
Chief Scientific Officer
Jane Hughes
  Jane  Hughes LinkedIn Profile  Jane  Hughes Twitter Account  Jane  Hughes News  Jane  Hughes on Facebook
Chief Technical Officer
Ashley Taylor
  Ashley Taylor LinkedIn Profile  Ashley Taylor Twitter Account  Ashley Taylor News  Ashley Taylor on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/25/2023: PMI Electro Mobility Solutions venture capital transaction
Next: 10/25/2023: Canopy Connect venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary